Ocular side-effects associated with imatinib mesylate (Gleevec).
This retrospective case series describes ocular side-effects associated with imatinib mesylate (Gleevec) and the clinical characteristics of these adverse reactions. A chart review of 104 patients on imatinib mesylate therapy from Oregon Health & Science University's Cancer Center were studied with regard to ocular side-effects. In addition, spontaneous reports from the Food and Drug Administration, the World Health Organization, and the National Registry of Drug-Induced Ocular Side-Effects databases were reviewed, including a Medline literature search. Seventy-three (70%) of the patients at OHSU developed periorbital edema and 19 patients (18%) developed epiphora after receiving imatinib mesylate. Average dose was 407.5+/-60 mg. Periorbital edema occurred an average of 68+/-48 days after initiation of therapy. WHO classification of side-effects is as follows: certain: periorbital edema; probable: epiphora; possible: extraocular muscle palsy, ptosis, blepharoconjunctivitis; unlikely: glaucoma, papilledema, retinal hemorrhage, photosensitivity, abnormal vision, and increased intraocular pressure. Periorbital edema and epiphora are the two most common ocular side-effects related to imatinib mesylate therapy. Clinical characteristics of imatinib mesylate induced periorbital edema are described. Management of ocular side-effects is conservative except in very rare cases of visually significant periorbital edema.
Fraunfelder
Frederick W
FW
Casey Eye Institute, Portland OR 97201, USA. eyedrug@ohsu.edu
Solomon
Jonathan
J
Druker
Brian J
BJ
Esmaeli
Bita
B
Kuyl
Jennifer
J
D000328:Adult; D000368:Aged; D001549:Benzamides; D004487:Edema / Q000139:chemically induced / Q000188:drug therapy; D005128:Eye Diseases / Q000139:chemically induced* / Q000145:classification* / Q000188:drug therapy; D006801:Humans; D000068877:Imatinib Mesylate; D007766:Lacrimal Apparatus Diseases / Q000139:chemically induced / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D013997:Time Factors; D014481:United States
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate